Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis

Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis

(2013) Catherine MacLean et al.   ANNALS OF INTERNAL MEDICINE

Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis

(2012) T. Lin et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women

(2011) Robert B Hopkins et al.   BMC MUSCULOSKELETAL DISORDERS

Bisphosphonate Use and Femoral Fractures in Older Women

(2011) Christian M. Girgis   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effects of denosumab on fracture and bone mineral density by level of kidney function

(2011) Sophie A Jamal et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Bone remodeling in postmenopausal women who discontinued denosumab treatment: Off-treatment biopsy study

(2011) Jacques P Brown et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Treatment with Denosumab Reduces the Incidence of New Vertebral and Hip Fractures in Postmenopausal Women at High Risk

(2011) S. Boonen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass

(2011) Henry G. Bone et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Bisphosphonate Use and Atypical Fractures of the Femoral Shaft

(2011) Jörg Schilcher et al.   NEW ENGLAND JOURNAL OF MEDICINE

If you don't take it – it can't work: the consequences of not being treated or nonadherence to osteoporosis therapy

(2011) Rick Adachi et al.   Therapeutics and Clinical Risk Management

Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density

(2010) H.K. Genant et al.   BONE

Denosumab and bisphosphonates: Different mechanisms of action and effects

(2010) Roland Baron et al.   BONE

2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary

(2010) A. Papaioannou et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Physician perception of patient adherence compared to patient adherence of osteoporosis medications from pharmacy claims

(2010) R. Copher et al.   CURRENT MEDICAL RESEARCH AND OPINION

Microarchitectural deterioration of cortical and trabecular bone: Differing effects of denosumab and alendronate

(2010) Ego Seeman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research

(2010) Elizabeth Shane et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of denosumab on bone turnover markers in postmenopausal osteoporosis

(2010) Richard Eastell et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate

(2010) D. L. Kendler et al.   OSTEOPOROSIS INTERNATIONAL

Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba cohorts

(2010) W. D. Leslie et al.   OSTEOPOROSIS INTERNATIONAL

Denosumab for the Management of Postmenopausal Osteoporosis

(2010) Andrea Singer et al.   POSTGRADUATE MEDICINE

Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study

(2009) G. Ioannidis et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy

(2009) David L Kendler et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Bisphosphonate Associated Osteonecrosis of the Jaw

(2009) A. A. KHAN et al.   JOURNAL OF RHEUMATOLOGY

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass

(2009) D. L. Kendler et al.   OSTEOPOROSIS INTERNATIONAL

Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis

(2009) I. Imaz et al.   OSTEOPOROSIS INTERNATIONAL

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial

(2008) Paul D. Miller et al.   BONE

Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial*

(2008) Jacques P Brown et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women

(2008) Henry G. Bone et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study

(2008) A. Papaioannou et al.   OSTEOPOROSIS INTERNATIONAL

Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study

(2008) B. A. Lenart et al.   OSTEOPOROSIS INTERNATIONAL